Posted from: Thursday, May 04, 2017 - 04:17 PM - Present

Lucentis Approved to Treat Diabetic Retinopathy

April 15, 2017 – The U.S. FDA approved a new indication for Lucentis® (ranibizumab) manufactured by Genentech. Lucentis had been approved to treat diabetic retinopathy in patients who also have diabetic macular edema (DME). Now, Lucentis can be used for all diabetic retinopathy patients, which according to the American Academy of Ophthalmology this is approximately 4 million Americans over the age of 40. It also is approved to treat wet age-related macular degeneration, macular degeneration due to obstructed retinal veins and myopic choroidal neovascularization (mCNV). Lucentis is a monoclonal antibody that is injected into the vitreous humor (jellylike filling of the eyeballs) by ophthalmologists who are specifically trained in its use. By blocking VEGF receptors, it lessens new blood vessel formation and helps to keep blood from seeping out of leaky vessels. For diabetic retinopathy patients, injections are given at one-month intervals.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Tuesday, November 21, 2017 - 06:32 AM.